23andMe Holding Co. (ME) EPS CAGR:N/A(TTM)
EPS CAGR uses precomputed diluted earnings history where available.
Over the past 12 months, 23andMe Holding Co.'s EPS CAGR is N/A.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how 23andMe Holding Co.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
ME EPS CAGR Chart
ME Quarterly EPS Growth (YoY)
EPS growth vs the same quarter one year earlier, last 17 quarters.
ME EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $-27.59 | $-10.88 | +$16.71 | N/A | N/A |
| 2024 | $-13.81 | $-27.59 | $-13.78 | N/A | N/A |
| 2023 | $-9.96 | $-13.81 | $-3.85 | N/A | N/A |
| 2022 | $-9.02 | $-9.96 | $-0.94 | N/A | N/A |
| 2021 | $-14.24 | $-9.02 | +$5.22 | N/A | N/A |
| 2020 | $-9.03 | $-14.24 | $-5.21 | N/A | N/A |
Quarterly EPS: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2025 | $-0.87 | +77.4% | +68.9% |
| Q4 2025 | $-3.85 | -91.5% | +55.2% |
| Q3 2024 | $-2.01 | +13.4% | +82.6% |
| Q2 2024 | $-2.32 | +17.1% | +26.8% |
| Q1 2024 | $-2.80 | +67.4% | +38.2% |
| Q4 2024 | $-8.59 | +25.7% | -205.7% |
| Q3 2023 | $-11.56 | -264.7% | -184.7% |
| Q2 2023 | $-3.17 | +30.0% | -7.8% |
| Q1 2023 | $-4.53 | -61.2% | -13.0% |
| Q4 2023 | $-2.81 | +30.8% | +11.9% |
| Q3 2022 | $-4.06 | -38.1% | +3.1% |
| Q2 2022 | $-2.94 | +26.7% | -263.0% |
| Q1 2022 | $-4.01 | -25.7% | -93.7% |
| Q4 2022 | $-3.19 | +23.9% | +3.3% |
| Q3 2021 | $-4.19 | -417.3% | -90.5% |
| Q2 2021 | $-0.81 | +60.9% | +54.5% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage